Results from the phase III head-to-head ENDEAVOR study comparing Kyprolis to Velcade in patients with relapsed multiple myeloma showed that patients treated with Kyprolis achieved progression-free survival of 18.7 months compared to 9.4 months (HR=0.53; 95% CI: 0.44, 0.65; p<0.0001).
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
